Analysts Offer Insights on Healthcare Companies: Check-Cap (NASDAQ: CHEK) and Matinas BioPharma (NASDAQ: MTNB)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Check-Cap (NASDAQ: CHEK) and Matinas BioPharma (NASDAQ: MTNB) with bullish sentiments.

Check-Cap (NASDAQ: CHEK)

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Check-Cap (NASDAQ: CHEK), with a price target of $5. The company’s shares opened today at $1.96.

Kolbert commented:

“Check-Cap announced a small capital raise of $2.69M gross proceeds with a single healthcare focused institutional investor for 1,349,000 shares at a price of $2.”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -16.1% and a 29.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Check-Cap is Moderate Buy and the average price target is $5.50, representing a 180.6% upside.

In a report issued on May 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $6 price target.
Matinas BioPharma (NASDAQ: MTNB)

In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Matinas BioPharma (NASDAQ: MTNB), with a price target of $6. The company’s shares opened today at $3.

McCarthy said:

“Matinas announced that the first set of data from the ongoing P2a study of MAT2203 (encochleated amphotericin, oral) will be presented at the American Society for Microbiology (ASM) June 1-5, 2017.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -12.6% and a 34.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Soleno Therapeutics Inc.

Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.